Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alfacell (ACEL) -- Ignore unavailable to you. Want to Upgrade?

To: Tom DuBois who wrote (1407)	6/23/1998 10:05:00 AM
From: Greg Kevorkian	Read Replies (2) \| Respond to of 1533

First, all the data that has been generated has to be computer analyzed, journals entries from the patients on side effects have to be compiled and analyzed and it all has to be put together. Though the trials are randomized there is a lot of info that has to be looked and and evaluated. P1 data and P2 data was good and there is no reason to believe that P3 should be any different. Tom D why are we at 3 bucks. Basically this company is a well kept secret. There are Oncologist that don't know about Onconase, I know that for a fact. There are many institutions that don't know about Alfacell. Plus at this stage of the game, why invest at $3 not knowing the data when you can wait a few more months and see what the results are, and invest with much less risk. It is the same with an agreement, any large company will wait to get the data results before signing an agreement, and if the data is good we are in a stronger position in the negotiations. If I were confident about the data, I would be silent myself. This is just my opinion. 2 more months will tell the story, at that point we will know who is right and who is wrong.

To: Tom DuBois who wrote (1407)	6/24/1998 6:17:00 PM
From: leighton stallones	Read Replies (2) \| Respond to of 1533

Yes Tom I am concerned that the stock is down at unreasonably low levels. There are many reasons for it and believe it or not most are not the fault of the company as such. They have been on a very tight budget not having resources of a major co who normally develop new drugs. Because of this and not having high profile execs like Amgen, Supergen they are not having early recognition. I dont believe nor do I anyone who believes the stock is down because of negative results in trials.Thats why we are in this situation because of our beliefs. With a limited amt of $ they can not put out a $15mm release to hype the stk everytime it needs help like some companies do. They are trying to finish this project as expeditiously as possible without running out of $. And yes the negative nonsense is and has been doing damage to this stock by discouraging new buyers which we need now to turn it up again.